Regenxbio (RGNX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Regenxbio (RGNX) do?
Regenxbio Inc (RGNX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops gene therapy candidates for retinal, neuromuscular, and metabolic diseases. It develops gene therapies and licenses its proprietary virus delivery system to outside pharmaceutical firms. It is worth $474.76M on the market and sold $154.14M over the last year.
- Market cap
- $474.76M
- P/E ratio
- None (reported a loss)
- Annual sales
- $154.14M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 19, 2026
RGNX’s flags, in plain English
Each flag is a number from Regenxbio’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.
Stupid Cash
Can pay this year's bills 4.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 77.8% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Insiders Hold
Insiders own 7.5% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Debt Is Driving
Heavy debt, 170% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about RGNX
How big is Regenxbio?
Regenxbio’s market cap is $474.76M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $154.14M: what customers paid the company over the last year, before any costs.
What is RGNX’s P/E ratio?
RGNX has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with RGNX?
The company depends heavily on royalty payments from Novartis for sales of Zolgensma. That is one risk on Regenxbio’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Regenxbio’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RGNX’s filings on SEC.gov. The Margin Monkey is research, not advice.
